Skinny Fit Max | GLP-3 Reta, MOTS-c & AOD-9604 Premium Metabolic Stack

Skinny Fit Max is a premium research stack combining GLP-3 Reta, MOTS-c, and AOD-9604. These three peptides are individually studied for their roles in tri-receptor metabolic signaling, mitochondrial energy regulation, and selective lipolytic activity. Their combination in a single research bundle enables investigation of three distinct but complementary fat metabolism pathways in controlled preclinical environments.

Key Properties

GLP-3 Reta:

• A tri-agonist peptide studied for simultaneous activation of GLP-1, GIP, and glucagon receptors, enabling investigation of multi-receptor metabolic coordination.
• Preclinical research examines its role in appetite modulation, glucose homeostasis, and adipose tissue dynamics via three distinct receptor systems.

MOTS-c:

• A mitochondrial-derived peptide investigated for its role in AMPK pathway activation and metabolic gene expression through nuclear retrograde signaling.
• Studies document its involvement in insulin sensitivity improvement and cellular energy regulation in rodent metabolic models.

AOD-9604:

• A synthetic C-terminal fragment of human growth hormone studied for selective beta-adrenergic receptor-mediated lipolytic activity in adipose tissue.
• Research documents significant fat mass reductions in obese mouse models without the insulin-desensitizing effects of full-length HGH.

Applications in Research

Skinny Fit Max is studied in laboratory settings investigating:

• Multi-receptor metabolic coordination and appetite regulation (GLP-3 Reta).
• Mitochondrial energy pathway activation and insulin sensitivity (MOTS-c).
• Peripheral lipolysis and adipose tissue remodeling (AOD-9604).

Research is conducted in controlled laboratory environments to explore the biochemical pathways these three peptides influence independently and in combination.

Component Research Breakdown

GLP-3 Reta: Triple Receptor Agonist for Metabolic Research

GLP-3 Reta is a tri-agonist peptide studied for its ability to activate three distinct receptor systems: GLP-1R, GIPR, and the glucagon receptor. That triple receptor engagement sets it apart from single-agonist GLP-1 compounds and dual-agonist GIP/GLP-1 peptides. Preclinical models have examined GLP-3 Reta's influence on energy expenditure, adipose tissue biology, and glucose regulation under conditions where stimulating all three pathways simultaneously provides broader metabolic coverage. See the GLP-3 Reta product page for standalone research options.

MOTS-c: Mitochondrial-Derived Metabolic Regulator

MOTS-c is encoded within the mitochondrial genome and acts as a retrograde signal to the nucleus, influencing metabolic gene expression through the folate-AICAR-AMPK pathway. The 2015 Lee et al. characterization in Cell Metabolism demonstrated MOTS-c's role in insulin sensitivity and obesity-related metabolic dysfunction in rodent models. It occupies the mitochondrial-nuclear signaling axis that neither GLP-3 Reta nor AOD-9604 address, making it a complementary addition to any metabolic research protocol. See the MOTS-c product page for additional research context.

AOD-9604: C-Terminal HGH Fragment for Lipolytic Research

AOD-9604 spans amino acids 176 to 191 of human growth hormone and has been studied specifically for its lipolytic activity through beta-adrenergic receptor-dependent mechanisms. In obese mouse models, AOD-9604 produced significant reductions in adipose tissue without affecting IGF-1 levels or glucose metabolism, distinguishing it from full-length HGH. That peripheral, adipose-specific action complements both the central appetite mechanisms of GLP-3 Reta and the mitochondrial energy regulation of MOTS-c. See the AOD-9604 product page for more information.

Synergistic Research Rationale

The Skinny Fit Max combination enables investigation of three non-overlapping metabolic axes in a single research protocol:

• Central and peripheral receptor coordination via GLP-1R, GIPR, and glucagon receptor co-activation (GLP-3 Reta)
• Mitochondrial energy metabolism via AMPK/AICAR nuclear signaling (MOTS-c)
• Peripheral adipose lipolysis via beta-adrenergic adipose receptor signaling (AOD-9604)

The combination's research value is in its ability to probe all three axes simultaneously. GLP-3 Reta handles receptor-level appetite and metabolic signaling, MOTS-c addresses the intracellular mitochondrial-nuclear axis, and AOD-9604 focuses on the adipose tissue end-organ response. That breadth makes Skinny Fit Max a practical tool for researchers designing multi-pathway metabolic studies. For protocol design guidance, see our Stacking Peptides Research Guide.

Storage and Handling Instructions

• Store all peptides in lyophilized form at -4 degrees F (-20 degrees C) or lower to maintain stability.
• Protect from light, moisture, and excessive heat throughout storage.
• Reconstitute each component separately with sterile bacteriostatic water immediately before use in the research protocol.
• Discard unused reconstituted solutions following institutional research protocols and biosafety guidelines.

Frequently Asked Questions

What is Skinny Fit Max?
Skinny Fit Max is a premium metabolic research stack combining GLP-3 Reta, MOTS-c, and AOD-9604 to enable multi-pathway investigation of fat metabolism, mitochondrial energy regulation, and receptor-level metabolic signaling in preclinical models.

How does Skinny Fit Max differ from the Skinny Fit Stack?
Skinny Fit Max replaces GLP-1 Sema with GLP-3 Reta, a tri-agonist peptide that activates GLP-1R, GIPR, and the glucagon receptor simultaneously. That triple receptor engagement enables broader metabolic pathway coverage than the single GLP-1 receptor focus of GLP-1 Sema, making it suited for researchers specifically studying multi-agonist metabolic mechanisms.

How should Skinny Fit Max components be stored?
Store all three components lyophilized at -20 degrees C or lower, protected from light and moisture. Reconstitute each peptide separately with sterile bacteriostatic water immediately before use. Post-reconstitution solutions should be handled under appropriate biosafety conditions.

What purity standards apply to each component?
Each component (GLP-3 Reta, MOTS-c, and AOD-9604) is tested to greater than or equal to 98% purity by HPLC with mass spectrometry identity confirmation before inclusion in the stack.

References

1. Lee C, Zeng J, Drew BG, et al. "The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance." Cell Metab. 2015;21(3):443-54. PubMed
2. Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. "Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone." Horm Res. 2000;53(6):274-8. PubMed
3. Finan B, Yang B, Ottaway N, et al. "A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents." Nat Med. 2015;21(1):27-36. PubMed